Anacor Pharmaceuticals, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Revenues:
Distribution and commercialization agreement
Research contracts
Total revenues
Operating expenses (income):
Cost of Goods Sold
Research and development
Selling, general and administrative
Trademark agreement
Litigation settlement gain
Total operating expenses (income)
Income (loss) from operations
Interest income
Interest expense
Gain (loss) on early extinguishment of debt
Other expense
Income (loss) before provision for (benefit from) income taxes
Provision for (benefit from) income taxes
Net income (loss)
Net loss per common share-basic and diluted (in dollars per share)
Net income (loss) per share:
Basic (in dollar per share)
Diluted (in dollars per share)
Weighted-average number of shares and equivalent shares:
Basic (in shares)
Diluted (in shares)
Weighted-average number of common shares used in calculating net loss per common share-basic and diluted (in shares)

Comments